Zimmer Biomet Holdings, Inc. $ZBH Stock Position Decreased by Ariel Investments LLC

Ariel Investments LLC decreased its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 15.6% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 253,190 shares of the medical equipment provider’s stock after selling 46,733 shares during the quarter. Ariel Investments LLC owned about 0.13% of Zimmer Biomet worth $23,093,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Chicago Partners Investment Group LLC grew its position in Zimmer Biomet by 3.3% in the second quarter. Chicago Partners Investment Group LLC now owns 3,865 shares of the medical equipment provider’s stock worth $376,000 after acquiring an additional 124 shares in the last quarter. Private Trust Co. NA increased its position in Zimmer Biomet by 14.6% during the second quarter. Private Trust Co. NA now owns 1,073 shares of the medical equipment provider’s stock worth $98,000 after buying an additional 137 shares during the last quarter. Brooklyn Investment Group raised its holdings in Zimmer Biomet by 45.9% during the first quarter. Brooklyn Investment Group now owns 461 shares of the medical equipment provider’s stock valued at $52,000 after buying an additional 145 shares in the last quarter. IFP Advisors Inc lifted its position in shares of Zimmer Biomet by 8.3% in the second quarter. IFP Advisors Inc now owns 1,947 shares of the medical equipment provider’s stock worth $178,000 after buying an additional 149 shares during the last quarter. Finally, Cary Street Partners Investment Advisory LLC lifted its position in shares of Zimmer Biomet by 83.7% in the second quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock worth $30,000 after buying an additional 149 shares during the last quarter. Institutional investors own 88.89% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $100.00 price objective (down from $115.00) on shares of Zimmer Biomet in a research note on Thursday, November 6th. Stifel Nicolaus set a $110.00 price target on shares of Zimmer Biomet in a research report on Wednesday, November 5th. Wall Street Zen cut shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a research note on Sunday, November 16th. Rothschild Redb upgraded shares of Zimmer Biomet to a “strong-buy” rating in a research note on Thursday, September 18th. Finally, Barclays cut their target price on shares of Zimmer Biomet from $112.00 to $105.00 and set an “underweight” rating for the company in a research report on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $109.00.

Zimmer Biomet Stock Down 0.4%

ZBH stock opened at $92.37 on Wednesday. Zimmer Biomet Holdings, Inc. has a twelve month low of $85.33 and a twelve month high of $114.44. The company has a quick ratio of 1.39, a current ratio of 2.43 and a debt-to-equity ratio of 0.59. The company has a market cap of $18.31 billion, a PE ratio of 22.86, a price-to-earnings-growth ratio of 2.44 and a beta of 0.61. The business’s 50-day simple moving average is $96.07 and its 200 day simple moving average is $96.76.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.88 by $0.02. The company had revenue of $2 billion during the quarter, compared to the consensus estimate of $2.01 billion. Zimmer Biomet had a return on equity of 12.85% and a net margin of 10.05%.The company’s quarterly revenue was up 9.6% on a year-over-year basis. During the same quarter last year, the company earned $1.74 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.